NCT06686134 Comprehensive Clinical Evaluation Study of GLP-1RA
| NCT ID | NCT06686134 |
| Status | Recruiting |
| Phase | — |
| Sponsor | LI YAN |
| Condition | T2DM |
| Study Type | OBSERVATIONAL |
| Enrollment | 492 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 492 participants in total. It began in 2024-07-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this project is to identify the most efficacious glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of adult patients with type 2 diabetes mellitus (T2DM). In accordance with the index system and evaluation rules set forth in the Management Guidelines for Comprehensive Clinical Evaluation of Drugs, the effects of GLP-1RAs drugs in real-world settings are tracked, summarised, and analysed across six dimensions: safety, effectiveness, economy, innovation, appropriateness, and accessibility. This is done with the objective of ensuring that these drugs are fully utilised in accordance with their potential benefits. The objective is to ascertain the role of medical institutions as the principal entity responsible for the comprehensive evaluation of the clinical application of drugs and to provide data that will reduce the risk of using GLP-1RAs drugs. Moreover, the objective is to ascertain the advantages of their clinical application and to guarantee the safe and rational use of drugs for patients with type 2 diabetes mellitus. The objective of this study is to facilitate the fulfilment of medical institutions' role as the primary entity responsible for the comprehensive evaluation of the clinical application of medicines. Furthermore, the study will provide data that can be used to reduce the risk of using GLP-1RAs drugs, explore the advantages of their clinical application, and guarantee the safe and rational use of medicines for patients with type 2 diabetes.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with type 2 diabetes; * no study drug has been used in the last three months; * Existing hypoglycemic programs include investigational drugs; * Age ≥18 years old; * The patient's demographic data, disease history, course records, laboratory test indicators, drug use and other information were complete; * Sign informed consent. Exclusion Criteria: * persistent influenza, autoimmune disease, or other metabolic disease; * There are obvious gastrointestinal diseases, gastrointestinal resection or malabsorption syndrome; * diet drugs, glucocorticoids, drugs affecting gastrointestinal motility are being used; * Patients with severe liver and kidney function impairment and patients with malignant tumors; * Pregnant or lactating women.
Contact & Investigator
Dong Zhonghua The First Affiliated Hospital of Shandong First Medical Univer, master
✉ dzh941213@163.com📞 +8618253161252
Yining Dong, pharmacist
PRINCIPAL INVESTIGATOR
Shandong Third Hospital
Frequently Asked Questions
Who can join the NCT06686134 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying T2DM. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06686134 currently recruiting?
Yes, NCT06686134 is actively recruiting participants. Contact the research team at dzh941213@163.com for enrollment information.
Where is the NCT06686134 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT06686134 clinical trial?
NCT06686134 is sponsored by LI YAN. The principal investigator is Yining Dong, pharmacist at Shandong Third Hospital. The trial plans to enroll 492 participants.